Live biotherapeutic products (LBPs), or next-generation probiotics (NGPs), are a type of product that contains a live microorganism and can prevent, treat, or cure human diseases. With the advances in synthetic biology and biological system engineering, commensal relationships between microbes and humans have been discovered. Meanwhile, novel NGPs have been investigated based on their therapeutic effects, such as Lactobacillus spp. As an advanced service provider in NGPs discovery, Creative Biolabs has expanded its expertise in microbiota and microbiome science and developed a Live Biotherapeutics platform for NGPs identification, characterization, analyses & qualification, and scale-up GMP manufacturing.
Lactobacillus spp. belong to the genus Lactobacillus, family Lactobacillaceae. They are part of the normal human flora and are generally assumed to be nonpathogenic, psychrophilic, non-spore-forming, rod-shaped, non-motile, Gram-positive, and facultatively anaerobic. Clinical and experimental evidence has claimed the potential role of Lactobacillus spp. as probiotics in the prevention or treatment of various diseases. They have shown anticarcinogenic, antimutagenic, and antitumorigenic activities in different animal models, especially in inflammatory bowel disease. The potential mechanism may be the direct immunomodulatory activity of Lactobacillus spp. that elicits anti-inflammatory effects in the intestine.
Fig.2 Different roles played by the beneficial microbes in innate and adaptive immune response by suppression and proliferation of immune cells. (El-Dalatony, 2020)
As one promising NGP candidate, Lactobacillus spp. shows great promise in clinical therapeutics. Engineered Lactobacillus spp. strains have been designed to target (a) pathogenic microbes, (b) molecules that may lead to a pathological condition, and (c) specific disease states.
Accumulated evidence has revealed an important relationship between Lactobacillus spp. and inflammatory bowel diseases (IBD). Daily supplementation with probiotic Lactobacillus spp. has been effective at ameliorating intestinal inflammation in human patients with IBD. In addition, probiotic formulations with Lactobacillus spp. are effective for the prevention or treatment of IBD-related pouchitis.
It has been an appreciation that increasing LDL-cholesterol (LDL-C) is a high risk for coronary artery disease (CAD). Jones et al. reported that bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 capsules can reduce LDL-C level and inhibit sterol absorption, indicating that Lactobacillus reuteri is an effective adjunctive therapy for treating hypercholesterolemia.
Lactobacillus casei (L. casei) has been shown to affect the tissue-specific autonomic nerves through the vagal nerve pathway to modulate glucose and lipid metabolism. It plays protective roles against nonalcoholic fatty liver disease (NAFLD) by decreasing hepatic steatosis and plasma alanine-amino transferase levels, as well as activating the Toll like receptor 4 signaling cascade in the liver.
L. casei has been reported to express and deliver human lactoferrin (hLF) to protect the host against bacterial infection, such as E. coli infection. Orally-administered L. casei significantly decreased intestinal injury and increased villi length to elicit antibacterial activity and protective effect.
Several probiotic strains belonging to Lactobacillus spp. have been claimed to possess anti-inflammatory, anti-infectious activities in different animal models. With industry-leading expertise and state-of-the-art single-use equipment, Creative Biolabs has pioneered the discovery of various Lactobacillus spp. as promising NGPs. Our comprehensive services include but not limited to new NGP identification, characterization, analyses & qualification, and scale-up GMP manufacturing.
|Lactobacillus casei||Lactobacillus crispatus||Lactobacillus delbrueckii||Lactobacillus gasseri|
|Lactobacillus jensenii||Lactobacillus plantarum||Lactobacillus reuteri||Lactobacillus rhamnosus 35|
|Lactobacillus rhamnosus GG||Lactobacillus salivarius|
NGPs targeting specific diseases have been used as a revolutionary class of medicines for therapeutic purposes. With our state-of-the-art technology and industry-leading expertise, Creative Biolabs has discovered a wide range of potential NGPs, including Lactobacillus spp., for pre-clinical, clinical, and commercial applications. In addition, we also provide customized services to meet specific demands. If you want to know more about our NGP discovery platform, please directly send us an e-mail or contact us for your special request.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.